News

Zydus Cadila’s secret scratch code in critical drug packs to help fight counterfeit menace

Drug firm Zydus Cadila has said that it has introduced a new feature in the packaging of its critical drugs to help patients ensure that the product is not fake or counterfeited.

To start with, technology is being implemented in the company’s products Remdac (Remdesivir) and Virafin Inj (Pegylated Interpheron Alpha 2b) and will be seen on the product packs in the third week of June, the drug firm said in a statement.

The feature will also be extended to other products of the company, it added.

The company said it has incorporated a new IT-enabled scratch code which shall be printed under a scratchable surface.

The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website, it added.

“The problem of counterfeit drugs undermines the painstaking efforts that are put in to ensure that the end user or patients receive a product that is safe and manufactured with the highest standards of quality excellence.

“Counterfeit drugs can be harmful as they may not have the desired outcome and could also be life threatening in some cases,” Cadila Healthcare Managing Director Sharvil Patel noted.

To curb this menace, the company has looked at a user-friendly solution which can reassure the patient that the product is genuine and safe, he added.

Cadila Healthcare is the listed entity of the Ahmedabad-based Zydus Cadila group which employs nearly 25,000 people worldwide, including 1,400 scientists in R&D.

Zydus Cadila Q4 net profit up 73% to 679 cr

Cadila Healthcare Limited, reported a growth of 73% in net profit on a consolidated basis to 679 crore in the January-March quarter of the financial year 2020-21.

As per a regulatory filing by the multinational pharmaceutical company to the stock exchanges on Thursday, May 27, Cadila Healthcare reported a net profit of 391 crore in the corresponding quarter of the previous fiscal.

The company’s board of directors recommended a final dividend of 3.50, or at 350%, per equity share of Re 1 each, upon the approval of shareholders. The company will make the payment of the dividend on or after August 16, 2021, after the approval.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!


Source link